Trials / Completed
CompletedNCT04450290
Dexamethasone-Eluting Cochlear Implant Electrode
Dexamethasone-Eluting Cochlear Implant Electrode (CIDEXEL): A First in Human Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- MED-EL Elektromedizinische Geräte GesmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma. The aim of this clinical investigation is to obtain a first experience in use of the investigational device in the adult clinical population, and to initially assess tools, techniques and performance outcome measures that may be considered in future clinical studies of similar devices.
Detailed description
The principal objective of this study is to exploratively investigate the safety profile of the device which will be evaluated through the analysis of adverse events during the follow-up period. For the study to be considered a success, the results of the adverse event analysis shall never cause an unbalanced risk vs. benefit assessment. The secondary objectives of this study aim at investigating the usefulness of possible outcome measures in evaluating the performance of the device.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CIDEXEL implant | The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma. |
Timeline
- Start date
- 2020-06-30
- Primary completion
- 2022-05-05
- Completion
- 2022-05-05
- First posted
- 2020-06-29
- Last updated
- 2022-06-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04450290. Inclusion in this directory is not an endorsement.